פולקס 400 ישראל - עברית - Ministry of Health

פולקס 400

sam-on ltd - ferrous as fumarate; folic acid - טבליה - folic acid 400 mcg; ferrous as fumarate 100 mg - ferrous fumarate - ferrous fumarate - for the prevention and treatment of iron deficiency anemia and for maintaining the level of folic acid particular in pregnancy.

אוויפלרה ישראל - עברית - Ministry of Health

אוויפלרה

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

אוויפלרה ישראל - עברית - Ministry of Health

אוויפלרה

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

טקפידרה 120 מג ישראל - עברית - Ministry of Health

טקפידרה 120 מג

medison pharma ltd - dimethyl fumarate - dimethyl fumarate 120 mg - dimetyl fumarate

טקפידרה 120 מג ישראל - עברית - Ministry of Health

טקפידרה 120 מג

medison pharma ltd - dimethyl fumarate - dimethyl fumarate 120 mg - dimetyl fumarate

טקפידרה 120 מג ישראל - עברית - Ministry of Health

טקפידרה 120 מג

medison pharma ltd - dimethyl fumarate - dimethyl fumarate 120 mg - dimetyl fumarate

טקפידרה 120 מג ישראל - עברית - Ministry of Health

טקפידרה 120 מג

medison pharma ltd - dimethyl fumarate - dimethyl fumarate 120 mg - dimetyl fumarate

טקפידרה 120 מג ישראל - עברית - Ministry of Health

טקפידרה 120 מג

medison pharma ltd - dimethyl fumarate - dimethyl fumarate 120 mg - dimetyl fumarate

טקפידרה 240 מג ישראל - עברית - Ministry of Health

טקפידרה 240 מג

medison pharma ltd - dimethyl fumarate - dimethyl fumarate 240 mg - dimetyl fumarate

טקפידרה 240 מג ישראל - עברית - Ministry of Health

טקפידרה 240 מג

medison pharma ltd - dimethyl fumarate - dimethyl fumarate 240 mg - dimetyl fumarate